Rigel Pharmaceuticals (RIGL) Operating Margin (2010 - 2026)

Rigel Pharmaceuticals' Operating Margin history runs 16 years deep, the most recent figure standing at 20.21% for Q1 2026.

• On a quarterly basis, Operating Margin fell 374.0% year-over-year to 20.21% in Q1 2026; TTM through Mar 2026 was 41.56%, a 1993.0% increase from a year earlier, with the FY2025 full-year figure at 42.63%, up 2914.0% from the prior year.
• Operating Margin retreated to 20.21% in Q1 2026 per RIGL's latest filing, from 33.19% in the prior quarter.
• Across five years, Operating Margin topped out at 60.09% in Q2 2025 and bottomed at 156.92% in Q1 2022.
• The 5-year median for Operating Margin is 4.05% (2022), against an average of 8.64%.
• Biggest YoY gain for Operating Margin was 10900 bps in 2022; the steepest drop was 20846 bps in 2022.
• Year by year, Operating Margin stood at 4.05% in 2022, then surged by 35 bps to 5.49% in 2023, then surged by 426 bps to 28.92% in 2024, then advanced by 15 bps to 33.19% in 2025, then sank by 39 bps to 20.21% in 2026.
• Per Business Quant, the three latest RIGL Operating Margin figures stand at 20.21% (Q1 2026), 33.19% (Q4 2025), and 40.91% (Q3 2025).